GC Therapeutics (GCTx), a biotech company founded in 2019, has captured the spotlight with its pioneering approach to cell therapy. With a mission centered on advanced induced pluripotent stem cell (iPSC)-based medicines, GCTx is driven by its innovative TFome platform. Bolstered by a successful
September 19, 2024The landscape of cell therapy manufacturing is on the brink of transformation as Cellares, an Integrated Development and Manufacturing Organization (IDMO), partners with Sony Corporation to integrate advanced cell analysis and sorting technologies into an already sophisticated manufacturing
September 13, 2024The world of cell therapy manufacturing is on the verge of a significant transformation. The partnership between Cellares, a leader in automated cell therapy manufacturing, and Sony Corporation, a technological giant renowned for its advanced flow cytometry, promises to reshape this burgeoning
September 12, 2024The recent partnership between Somite Therapeutics and OmniaBio Inc. marks a promising leap forward in treating Duchenne muscular dystrophy (DMD). Combining Somite's AI-driven approach with OmniaBio's cell and gene therapy expertise, this collaboration aims to expedite the development of
September 10, 2024Sarepta Therapeutics recently revealed financial results that indicate lower-than-expected sales for its flagship gene therapy product, Elevidys, designed to treat Duchenne muscular dystrophy (DMD). The sales figures for the second quarter fell short of Wall Street's projections, raising
September 9, 2024Autoimmune diseases, affecting millions of people worldwide, present a unique challenge where the body's immune system mistakenly attacks its tissues. Existing treatments primarily rely on immunosuppressants, which often come with severe side effects and don’t always offer a cure. Enter Candid
September 9, 2024